Clinical Trial Access in Low- and Middle-Income Countries: A Case Study on India
- 1 September 2021
- journal article
- editorial
- Published by Taylor & Francis Ltd in Cancer Investigation
- Vol. 39 (9), 685-689
- https://doi.org/10.1080/07357907.2021.1912078
Abstract
The global burden of cancer is estimated to be more than 20 million cases by 2030, the majority occurring in low- and middle- income countries (LMICs).1 LMICs account for 64% of global cancer death...Keywords
This publication has 14 references indexed in Scilit:
- Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial ParticipationJNCI Journal of the National Cancer Institute, 2019
- Disparities in Breast, Lung, and Cervical Cancer Trials WorldwideJournal of Global Oncology, 2018
- Prospective registration of cancer clinical trials in India.Journal of Clinical Oncology, 2018
- Compensation to clinical trial participants in India: A gap analysisInternational Journal of Pharmaceutical Investigation, 2017
- The global burden of women’s cancers: a grand challenge in global healthThe Lancet, 2016
- Rights violation found in HPV vaccine studies in IndiaThe Lancet Oncology, 2013
- Global cancer transitions according to the Human Development Index (2008–2030): a population-based studyThe Lancet Oncology, 2012
- Standing committee report on CDSCO: hard facts confirm an open secret.Indian Journal of Medical Ethics, 2012
- Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countriesBulletin of the World Health Organization, 2011
- Breast Cancer in Developing Countries: Opportunities for Improved SurvivalJournal of Oncology, 2010